AHA 2018

Previous studies on the suitability of diuretics for patients with hypertension and diabetes reveal inconsistencies.

Coagulant activity was improved with the use of both anticoagulation and antihypertensive therapies in combination.

Researchers aimed to find the optimal dose and regimen of AKCEA-APO(a)-LRX injected subcutaneously for further clinical development.

Dapagliflozin was not associated with either a higher or lower rate of MACE compared with placebo in patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease.

Low-dose methotrexate did not result in a reduced number of cardiovascular events among patients with stable atherosclerosis.

Meta-analysis suggests that calcium channel blockers can be effective in preventing peripheral arterial disease in patients with hypertension.

While the use of NSAIDs was low in the ARISTOTLE trial, NSAID users had a higher risk for bleeding than non-users.

In high-risk patients with mild hypertriglyceridemia, omega-3 fatty acids improved triglyceride levels and reduced major adverse cardiovascular events, according to a new meta-analysis.

A sacubitril-valsartan therapy regimen was associated with greater reductions in NT-proBNP concentrations in patients with HFrEF compared with enalapril.

Updated cholesterol guidelines offer more personalized cardiovascular disease risk assessment.